Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R

Podobne zapisy

• The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
  od: Yang, Chih-Jen, i wsp.
  Wydane: (2017)
• The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition
  od: Wu, Shang-Gin, i wsp.
  Wydane: (2016)
• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  od: Shang-Gin Wu, i wsp.
  Wydane: (2017-07-01)
• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  od: Wu, Shang-Gin, i wsp.
  Wydane: (2017)
• Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
  od: Kuwata, Taiji, i wsp.
  Wydane: (2016)